FC2ブログ

バイオの戯言

ライフサイエンスに関する話題についてコメント(戯言?)を述べていくブログです。

スポンサーサイト 

上記の広告は1ヶ月以上更新のないブログに表示されています。
新しい記事を書く事で広告が消せます。
[ --/--/-- --:-- ] スポンサー広告 | トラックバック(-) | コメント(-)

【プレスリリースメモ】 RNAi関係 (2013.2.9)  

<Alnylam Pharmaceuticals>
The Medicines Company and Alnylam Form Strategic Alliance to Develop and Commercialize RNAi Therapeutics Targeting PCSK9 for the Treatment of Hypercholesterolemia(2013.2.4)
Alnylam to Webcast Presentation at Upcoming Investor Conferences(2013.2.5)
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results(2013.2.7)

<Mesoblast>(Angioblast Systemsを買収)
Key Mesenchymal Precursor Cell Patents Granted in United States and China; New Granted Claims Confer Exclusive, Long-term Commercial Rights in the World's Largest Established and Eme(2013.2.7)

<Antisense Therapeutics>
Antisense Therapeutics to Present at BIO CEO & Investor Conference(2013.2.4)

<Arrowhead Research>
Arrowhead to Report Fiscal 2013 First Quarter Financial Results(2013.2.6)

<CytRx Corporation>
CytRx to Present at the BIO CEO & Investor Conference(2013.2.4)
CytRx to Present at the 2013 Leerink Swann Global Healthcare Conference(2013.2.6)

<Exiqon A/S>
Exiqon A/S - Exiqon reports full year results for 2012(2013.2.6)

<Galena Biopharma>
Galena Biopharma to Present at the 15th Annual Bio CEO & Investor Conference(2013.2.5)

<Generex Biotechnology>
Generex Touts Pipeline Potential of Antigen Express Subsidiary(2013.2.7)

<Genethon>
Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial for an inherited immune deficiency: chronic granulomatous disease(2013.2.5)

<iCo Therapeutics>
iCo Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference(2013.2.5)

<Idera Pharmaceuticals>
Idera to Present at the 15th Annual BIO CEO and Investor Conference(2013.2.5)

<Isis Pharmaceuticals>
Isis Pharmaceuticals to Present at the 2013 Leerink Swann Global Healthcare Conference(2013.2.7)

<OncoGenex Technologies>
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences(2013.2.5)

<OPKO Health>
Clarification Regarding Exercise and Sale of Common Stock Options by OPKO Health Company Officer(2013.2.)

<Prosensa>
Larry Bell, MD Joins Prosensa as Head of Global Regulatory Affairs(2013.2.7)

<Regulus Therapeutics>
Regulus to Present at Two Upcoming Investor Conferences(2013.2.4)

<Rosetta Genomics>
Study Validating Ability of microRNAs to Predict Progression of Bladder Cancer Published in British Journal of Urology International(2013.2.7)

<Sarepta Therapeutics>
Sarepta Therapeutics to Present Company Overview at the Leerink Swann Global Healthcare Conference(2013.2.4)

<Tekmira Pharmaceuticals>
Tekmira to Present TKM-PLK1 Phase 1 Clinical Trial Results at AACR(2013.2.4)
Tekmira to Webcast Presentation at 15th Annual BIO CEO & Investor Conference(2013.2.6)

<Vical>
Vical Announces Publication of Herpes Simplex Vaccine Guinea Pig Study Data(2013.2.4)
Vical to Present at February Investor Conferences(2013.2.5)
Vical Reports 2012 Financial Results and Progress in Key Development Programs(2013.2.6)

<アンジェスMG>
行使価額修正条項付新株予約権の大量行使に関するお知らせ(2013.2.5)
特別利益及び特別損失の発生並びに通期業績予想の修正に関するお知らせ(2013.2.6)
IR情報/IRライブラリー:決算短信等を更新しました(2013.2.7)


スポンサーサイト
[ 2013/02/09 11:30 ] プレスリリース | TB(0) | CM(0)
コメントの投稿













管理者にだけ表示を許可する
最新ニュース
お気に入り
カレンダー(月別)
11 ≪│2018/12│≫ 01
- - - - - - 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 - - - - -
特選品
特許関係の書籍-3
特許関係の書籍-2
特許関係の書籍-1
情報関係の書籍
月別アーカイブ
プロフィール

のぐひで

Author:のぐひで
FC2ブログへようこそ!



上記広告は1ヶ月以上更新のないブログに表示されています。新しい記事を書くことで広告を消せます。